Next generation protein degradation
Expanding Protein Degradation to Membrane and Extracellular Targets
We are a venture backed company with a mission to develop first-in-class and best-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.
Protein degradation has the potential to eliminate disease causing proteins that were previously not addressable by classical therapeutic approaches. First generation protein degradation approaches can degrade intracellular proteins but do not address membrane and extracellular proteins, which are approximately 40% of the proteome.
Our proprietary EpiTAC platform enables the development of first-in-class and best-in-class targeted therapies that degrade disease driving membrane and extracellular proteins. This approach can be effective against a wide range of disorders that lack meaningful treatment options today.
We are looking for talented individuals with experience across a number of scientific disciples including molecular biology, cloning, antibody engineering, antibody discovery & display, protein purification, biophysical characterization, cell biology, in-vivo biology and bioinformatics.
If you want to work with an exceptional team of scientists on next generation protein degradation technology, please send over your resume/CV using the link below.
We are actively building our incredible protein science and translational biology team.
Open Positions
Note to External Recruiters: Submission of unsolicited resumes prior to an agreement set in place does not create any implied obligation.
Contact Us
Our Office:
1900 Alameda de las Pulgas
Suite 250
San Mateo, CA 94403
General Inquiries:
info@epibiologics.com
Business
Development Inquiries: BD@epibiologics.com
Follow Us